Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Exploratory Clinical Study of Utidelone Combined With Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer That Has Failed Standard First-line Therapy

NCT05866510 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05866510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05866510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Exploratory Clinical Study of Utidelone Combined With Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer That Has Failed Standard First-line Therapy
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
May 15, 2023
Completion date
April 30, 2024
Enrollment
47 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer